Two major studies confirm the HPV vaccine is working to prevent cervical cancer, but where you live determines how much you benefit. A new analysis of US cancer data shows cervical cancer rates among women aged 20 to 31 have dropped 27% since HPV vaccination was introduced in 2006, yet some states have cut rates by more than half while others have seen almost no improvement. Meanwhile, a Swedish study tracking women for nearly two decades found no evidence that the vaccine's protection fades over time .

Which US States Are Winning the Battle Against Cervical Cancer?

Researchers at the American Cancer Society examined cervical cancer rates across 47 states and the District of Columbia to understand why progress has been so uneven. The findings were striking. In Washington DC, Rhode Island, Michigan, and Hawaii, cervical cancer rates in young women fell by more than 50% compared with the pre-vaccine years. An additional 28 states recorded declines between 15% and 50%. However, in ten states, declines were less than 15%, and in Vermont and West Virginia, rates did not meaningfully reduce during the study period .

The pattern directly mirrors HPV vaccination coverage across states.

"US states with higher HPV vaccination rates saw faster drops in cervical cancer. For every ten percentage-point increase in vaccine uptake, the relative decline in cancer rates was about 11% greater," the researchers noted.

Chenxi Jiang and colleagues, American Cancer Society

This connection held true even after accounting for differences in cervical cancer screening access between states .

What's Driving These Geographic Disparities?

The researchers emphasized that state-specific policies, healthcare infrastructure, and social factors are shaping how quickly cervical cancer is disappearing in different regions. Without more equitable implementation of HPV vaccination programs, the gaps between states could widen significantly. Some parts of the country could eliminate cervical cancer decades earlier than others, while women in states with lower vaccination rates may face higher risks as they age .

• Policy and Access: States with stronger political commitment to HPV vaccination programs and better healthcare infrastructure have achieved the fastest declines in cervical cancer rates among young women.
• Vaccination Coverage Rates: The direct relationship between vaccine uptake percentages and cancer rate reductions shows that increasing access to the HPV vaccine is the most effective lever for preventing cervical cancer.
• Screening Availability: Even with vaccination, access to cervical cancer screening remains important, though vaccination coverage appears to be the primary driver of the disparities observed.

How Long Does HPV Vaccine Protection Actually Last?

One critical question for eliminating cervical cancer is whether the vaccine's protection fades over decades. A large Swedish study published in the BMJ provides strong reassurance that it does not. The research followed more than 1.6 million girls and women over 11 years, building on a landmark 2020 study that was among the first to show HPV vaccination sharply reduced the risk of invasive cervical cancer in real-world settings .

The new Swedish analysis tracked women for up to 18 years after vaccination and found no evidence that protection fades. Those vaccinated before age 17 had around a 79% lower risk of invasive cervical cancer compared with unvaccinated women. This long-term protection is essential for countries aiming to eliminate cervical cancer entirely, since immunity must last for decades to prevent disease in adulthood .

Steps to Ensure Equal Access to HPV Vaccination Protection

• Strengthen State Policies: Advocate for stronger political commitment to HPV vaccination programs in your state, especially if your region has lower vaccination rates or slower progress in reducing cervical cancer.
• Increase Healthcare Infrastructure Investment: Support efforts to improve healthcare access in underserved communities, as infrastructure gaps directly affect vaccination coverage and cervical cancer prevention.
• Address Social Determinants: Work with local health organizations to address barriers to vaccination, including transportation, cost, and health literacy in communities with lower uptake rates.

The research makes clear that the HPV vaccine works. The US was the first country to introduce it in 2006, recommending it for 11- and 12-year-old girls and expanding guidance to include boys in 2011. But the vaccine only protects those who have access to it. Without more equitable implementation, existing geographic gaps in cervical cancer prevention will likely widen, leaving women in some regions at significantly higher risk than those in states with robust vaccination programs .